To test the utility of 3D liver microtissues for compound de-risking, we investigated the hypothesis that species differences in thyroxine metabolism by UGT could underlie differences in susceptibility to thyroid carcinogenesis in rats and humans. Using bioinformatic analysis of microarray and proteomics data derived from PB treated rat and human liver 3D microtissues, we found a differential effect in the induction of UGT isoforms between the two species, supporting a role for 3D microtissues in the investigation of adverse outcome pathways (AOPs) and discovery safety assessment.
Published in Toxicology Reports (Volume 8, 2021, Pages 155-161), the paper describes how our proprietary SpheroMatrices microTMA technology can be used to understand toxicity risk in discovery safety screening.
enquiries to: email@example.com
on an interactive, step by step basis. Collaborations can begin with pilot projects which can then be scaled up to larger research programs, according to your requirements.